このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

2026年11月11日 更新者:Fujian Cancer Hospital

This is a single-arm, phase II clinical study. A total of 43 treatment-naive hepatocellular carcinoma patients with portal vein tumor thrombus (PVTT) are planned to be enrolled. Eligible subjects will enter the study after signing informed consent.

Each subject will receive TAE-HAIC combined with Iparomlimab and Tuvonralimab (QL1706, 7.5 mg/kg, iv, Q3W) and lenvatinib (8 mg for body weight <60 kg, or 12 mg for body weight >60 kg, po, QD). QL1706 is administered on Day 2 of interventional therapy, with a 21-day cycle. Lenvatinib is taken orally on the day of discharge after QL1706 infusion. The HAIC cycles will be determined by investigators according to the subject's condition, ranging from 3 to 6 cycles.

QL1706 and lenvatinib can be maintained for up to 2 years, until disease progression (PD, comprehensively assessed by investigators based on imaging and clinical status), loss of clinical benefit, intolerable toxicity, withdrawal of informed consent, initiation of new anti-tumor therapy, or other treatment discontinuation criteria specified in the protocol, whichever occurs first. For subjects withdrawn due to PD, subsequent treatment options may include targeted agents (apatinib, regorafenib, ramucirumab), immunotherapy (pembrolizumab, camrelizumab, tislelizumab), traditional Chinese medicine preparations with indications for hepatocellular carcinoma, best supportive care or palliative care, in accordance with the 2025 CSCO or NCCN guidelines, at the investigator's discretion.

Contrast-enhanced CT or MRI (PET-CT when necessary) will be performed every 6 weeks (±7 days) from treatment initiation for efficacy assessment until PD, death, intolerable toxicity, withdrawal of consent, initiation of new anti-tumor therapy or other protocol-specified discontinuation reasons, whichever comes first. Subjects will continue safety visits and survival follow-up after treatment discontinuation. Safety follow-up lasts for 30 days after the last dose (90 days for immune-related adverse events). Survival follow-up is conducted every 3 months within 2 years and every 6 months thereafter up to 3 years after treatment discontinuation or death. For subjects stopping treatment for reasons other than PD or death, tumor progression follow-up including serum tumor markers (AFP, PIVKA-II (DCP)) and imaging examinations (dynamic contrast-enhanced MRI/CT of abdomen and pelvis) will be arranged.

TAE: particulate embolic agents such as gelatin sponge particles, blank microspheres and PVA particles are used to embolize tumor feeding arteries.

HAIC-FOLFOX regimen: oxaliplatin 85 mg/m² intra-arterial infusion over 2-3 h, leucovorin 400 mg/m² intra-arterial infusion over 1-2 h, fluorouracil 400 mg/m² intra-arterial bolus followed by continuous intra-arterial infusion of 2400 mg/m² for 23 h or 46 h, repeated every 3 weeks.

調査の概要

状態

まだ募集していません

条件

研究の種類

介入

入学 (推定)

43

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Zhuting Fang, MD
  • 電話番号:+8613805012709
  • メール:470389481@qq.com

研究場所

    • Fujian
      • Fuzhou、Fujian、中国
        • Fujian Cancer Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Aged between 18 and 75 years inclusive.

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, and Child-Pugh score ≤ 7.

  • Diagnosed by imaging or histopathology with BCLC stage C hepatocellular carcinoma complicated with portal-vein tumor thrombus (Vp1-4); extrahepatic metastases are permitted. The primary lesion is deemed unresectable by multidisciplinary team (MDT) assessment.

  • At least one measurable lesion according to RECIST 1.1 (longest diameter ≥ 10 mm for measurable lesion on spiral CT, or short-axis diameter ≥ 15 mm for malignant lymph node).

  • No prior systemic or locoregional therapies for hepatocellular carcinoma, including but not limited to chemotherapy, targeted therapy, immunotherapy, radiotherapy, surgery, hepatic arterial infusion chemotherapy (HAIC), transarterial chemoembolization (TACE), etc.

  • Expected survival ≥ 3 months.

  • Laboratory values obtained within 7 days prior to first study drug administration meet the following criteria (no blood products, hematopoietic growth factors, albumin, or other corrective therapies judged by the investigator permitted within 14 days before laboratory testing):

    1. Biochemistry: alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ 5 × upper limit of normal (ULN); total serum bilirubin (TBIL) ≤ 2 × ULN; serum creatinine ≤ 1.5 × ULN, or creatinine clearance > 50 mL/min (calculated by the Cockcroft-Gault formula); serum albumin ≥ 30 g/L.
    2. Hematology: hemoglobin (Hb) ≥ 9.0 g/dL; no red-blood-cell transfusion within 1 week (including the day of baseline Hb testing); absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelet count ≥ 75 × 10⁹/L; no platelet transfusion within 1 week (including the day of baseline platelet testing).
    3. Coagulation: international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. For subjects receiving prophylactic anticoagulation without active bleeding (i.e., no bleeding episode in the preceding 14 days), the investigator shall confirm that INR falls within a safe and effective therapeutic range.
    4. Urinalysis: urine protein < 2+ by dipstick or routine urinalysis; if urine protein ≥ 2+, 24-hour urinary protein quantification must be < 1 g/24 h.
  • No contraindications to chemotherapy, targeted agents or immunotherapy.

  • Women of child-bearing potential must have a negative serum pregnancy test within 7 days before enrollment, and agree to use reliable effective contraception throughout the study and for 3 months after the last study-drug dose. Male subjects with partners of child-bearing potential must agree to use reliable effective contraception throughout the study and for 3 months after the last study-drug dose. Lactating women are excluded.

  • The subject must be informed of the study prior to trial participation, voluntarily provide written informed consent, and be willing and able to comply with scheduled visits, treatment regimens, laboratory tests and other study-required procedures.

Exclusion Criteria:

  • Diffuse hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, etc., confirmed by imaging or cytology.
  • Any prior history of immunotherapy with any of the following: grade 3 or higher immune-related adverse events (irAEs); toxicities that led to permanent discontinuation of prior anti-PD-1/PD-L1 immunotherapy; disease progression assessed to occur within ≤ 3 months during previous immunotherapy.
  • Received treatment from another clinical trial within 4 weeks prior to the first study-drug administration, unless it is an observational (non-interventional) clinical trial or the subject is in the follow-up phase of an interventional trial; or received locoregional or systemic anti-cancer therapy within 28 days before the first study-drug administration.
  • History of allogeneic bone marrow transplantation or solid-organ transplantation, or active chronic graft-versus-host disease.
  • Symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage. Subjects with asymptomatic mild pleural effusion, ascites or pericardial effusion identified by imaging are eligible.
  • Presence of hepatic encephalopathy or central nervous system metastases.
  • For subjects positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb): HBV-DNA must be < 1 × 10⁴ copies/mL or 2000 IU/mL. Subjects with active hepatitis B must have received antiviral therapy for at least 14 days prior to enrollment (local standard-of-care agents such as entecavir or tenofovir are permitted), and agree to continue effective antiviral therapy during the study. HBV-DNA levels shall be monitored throughout treatment; antiviral therapy must be initiated once HBV-DNA turns positive and shall be maintained during the study and for 6 months after the last study-drug dose. Subjects positive for HCV antibody must undergo HCV-RNA testing; subjects with HCV-RNA > 1 × 10³ copies/mL are excluded.
  • History of esophageal or gastric variceal bleeding secondary to portal hypertension within the preceding 6 months; subjects judged by the investigator to be at high bleeding risk. Any life-threatening bleeding event within the preceding 3 months, including bleeding requiring transfusion, surgery, locoregional intervention, or ongoing medical management.
  • History of arterial or venous thromboembolic events within the preceding 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep-vein thrombosis, or any other serious thromboembolic event. Thrombosis related to implantable venous access ports or catheters, or superficial venous thrombosis stabilized under routine anticoagulation are excluded from this criterion. Prophylactic use of low-dose low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) is allowed.
  • Continuous use of aspirin (> 325 mg/day) or other known platelet-function inhibitors such as clopidogrel or ticlopidine within 2 weeks prior to first study-drug dose; known severe bleeding diathesis or coagulopathy; or ongoing thrombolytic therapy.
  • Abdominal wall fistula or gastrointestinal perforation, refractory non-healed gastric ulcer, active gastrointestinal bleeding, or definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, faecal occult blood ≥ 2+) without targeted therapeutic intervention within 6 months before enrollment.
  • Uncontrolled comorbidities, including but not limited to: persistent or active infection; symptomatic congestive heart failure (NYHA class II-IV with left-ventricular ejection fraction (LVEF) < 50% on echocardiogram); uncontrolled diabetes; uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite optimal medical therapy, history of hypertensive crisis or hypertensive encephalopathy); clinically significant cardiovascular disease; symptomatic or poorly controlled arrhythmias (congenital long-QT syndrome or corrected QTc > 500 ms calculated by Fridericia formula at screening); active interstitial lung disease or other pulmonary disorders with severe impairment of pulmonary function; history of nephropathy or nephrotic syndrome; severe chronic gastrointestinal disease accompanied by diarrhoea; or psychiatric/social conditions that may impair adherence to study procedures, substantially increase adverse-event risk, or compromise the subject's ability to provide written informed consent.
  • History of active primary immunodeficiency; human immunodeficiency virus (HIV) infection; active syphilis infection.
  • Active or clinically uncontrolled severe infection. Severe infection occurring within 4 weeks before first study-drug administration, including but not limited to hospitalization for infectious complications, sepsis, severe pneumonia, and active tuberculosis (currently receiving anti-tuberculosis therapy or having received anti-tuberculosis therapy within 1 year before first dosing).
  • Active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, corticosteroids, immunosuppressants) within 2 years prior to first study-drug administration. Replacement therapies (e.g., thyroxine, insulin, physiological-dose corticosteroids for adrenal or pituitary insufficiency) are permitted. For subjects with positive autoantibodies only, the investigator must confirm the absence of clinical autoimmune disease. Use of immunosuppressive agents within 4 weeks before first dosing is excluded, except for intranasal, inhaled or other topical corticosteroids, or physiologic-dose systemic corticosteroids (i.e., ≤ 10 mg prednisone per day or equivalent).
  • Received live-attenuated vaccine within 4 weeks prior to first study-drug administration, or planned to receive live-attenuated vaccine during the study.
  • Major surgery (craniotomy, thoracotomy, laparotomy) performed within 4 weeks before first study-drug administration, or unhealed wounds, ulcers or fractures; tissue biopsy or venepuncture for intravenous infusion are exempted.
  • Diagnosis of other malignant neoplasms within 5 years prior to first study-drug administration, except for basal-cell carcinoma of the skin, squamous-cell carcinoma of the skin, and/or radically resected carcinoma in-situ.
  • Known hypersensitivity to any study drug or any of its excipients.
  • Pregnant or lactating women.
  • Any other condition rendering the subject unsuitable for participation in this study, as judged by the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Experimental

TAE-HAIC Combined with Iparomlimab and Tuvonralimab (QL1706) and Lenvatinib

TAE-HAIC Combined with Iparomlimab and Tuvonralimab (QL1706) and Lenvatinib

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Objective Response Rate
時間枠:From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first

Percentage of participants achieving objective response (CR or PR) maintained for at least 4 weeks assessed per mRECIST

From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first

二次結果の測定

結果測定
メジャーの説明
時間枠
Duration of Response
時間枠:From first study treatment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)

Time from first documented objective response to disease progression or death

From first study treatment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)
Disease Control Rate
時間枠:From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first

Percentage of participants achieving disease control (CR or PR or SD) maintained for at least 4 weeks assessed per mRECIST

From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first
Progression-Free Survival
時間枠:From enrollment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)

Time from enrollment to first-documented disease progression per mRECIST or death from any cause, whichever occurs first

From enrollment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)
Overall Survival
時間枠:From enrollment until death from any cause (maximum participant follow-up 3 years after end of treatment)

Time from enrollment to death from any cause

From enrollment until death from any cause (maximum participant follow-up 3 years after end of treatment)
Incidence and severity of adverse events
時間枠:From first study treatment through 30 days after last study-drug dose; immune-related adverse events followed through 90 days after last study-drug dose

Treatment-emergent adverse events graded by CTCAE v5.0, including immune-related adverse events

From first study treatment through 30 days after last study-drug dose; immune-related adverse events followed through 90 days after last study-drug dose

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2030年3月1日

研究の完了 (推定)

2030年9月1日

試験登録日

最初に提出

2026年11月11日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant-level data (IPD) will not be shared. This is a single-site, investigator-initiated exploratory phase II study. Access to individual-level participant data is restricted per institutional data governance requirements and local patient-privacy regulations. Data sharing outside of the approved study scope is not pre-planned for this trial.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する